The price of the first generic medicine was close to the price of original brand medicine, where the first generic medicine to original brand medicine price ratio was 0.87–0.81. Some drugs or medical materials are banned in Saudi Arabia, and importing them into the country is illegal. The generic medicine to original brand medicine price ratio was 0.86–0.31. Value Health Reg Issues. 2013;13(1):390. innovator’s product, and its generic versions was conducted. In fact, the first generic medicine to original brand medicine ratio was only between 0.87–0.81. 5. DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025" report has been added to ResearchAndMarkets.com's offering. In: Babar ZUD, editor. Available from: https://www.sfda.gov.sa/en/drug/search/Pages/default.aspx. 3/2001 of the Inter-ministerial Committee for Economic Planning (CIPE), which has governed drug pricing for the past 19 years, and includes some important aspects related to transparency. This report will enhance your decision-making capability by allowing you to: • Develop business strategies by understanding the trends shaping and driving the Saudi Arabian healthcare market, • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future, • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors, • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership, • Identify, understand, and capitalize on the opportunities and challenges in the Saudi Arabian healthcare market, 2.3 Key Events: Saudi Arabian Pharmaceutical History, 2008–2019, 2.4 Key Events: Saudi Arabian Pharmaceutical Market, 2.5 Key Events: M&A, VC & PE Deals, Global Pharmaceutical Market, 2018–2019, 3.4 Pharmaceutical Market – Market Segments, 3.5 Pharmaceutical Market – Supply Channels, 3.6 Pharmaceutical Market – Top Five Disease Areas, 3.7 Pharmaceutical Market – Major Players, 4.2 Medical Device Market – Top Five Segments, 4.3 Medical Device Market – Diagnostic Market, 4.4 Medical Device Market – Major Players, 5 Pharmaceutical and Medical Device Market – Drivers and Barriers, 6.1 Deal Analysis: M&A, VF and PE Deals, Pharmaceutical Market, Saudi Arabia, 6.2 Deal Analysis: M&A, VF and PE Deals, Medical Device Market, Saudi Arabia, 7 Pharmaceutical and Medical Device Market – Porter’s Five Forces Analysis, 7.1 Pharmaceutical Market, Saudi Arabia – Porter’s Five Forces Analysis, 7.2 Medical Device Market, Saudi Arabia – Porter’s Five Forces Analysis, 8.1 Overview of Healthcare System, Saudi Arabia, 8.1.2 Healthcare Transformation, Saudi Arabia, 8.2.1 Overview of Insurance, Saudi Arabia, 8.2.2 Healthcare Spending and Medical Products Price Index, Saudi Arabia, 8.3.1 Market Authorization for Pharmaceutical Drugs, Saudi Arabia, 8.3.2 Market Authorization for Medical Devices, Saudi Arabia, 8.3.3 Pharmaceutical Establishment Regulations, Saudi Arabia, 8.3.5 Intellectual Property Rights, Patent, Saudi Arabia, 8.3.6 Intellectual Property Rights, Trademark, Saudi Arabia, 8.3.7 Clinical Trial Regulations, Saudi Arabia, 8.3.8 Pharmaceutical Advertising Regulations, Saudi Arabia, 8.3.9 Labeling and Packaging Regulations, Saudi Arabia, 9.7.2 Share of Public and Private Sectors, Table 1: Opportunities in Pharmaceutical and Biotech Clusters, Saudi Arabia, 2019, Table 2: Pharmaceutical Market, Saudi Arabia, Sales of Patented Drug Products by Major Therapeutic Class (%), 2010–2015, Table 3: Medical Device Market, Saudi Arabia, Revenue by Segment, Table 4: Nephrology and Urology Device Market, Saudi Arabia, Revenue ($M) and Market Share (%) of Major Companies, 2017, Table 5: Drug Delivery Devices Market, Saudi Arabia, Revenue ($B) and Market Share (%) of Major Companies, 2017, Table 6: Healthcare IT Market, Saudi Arabia, Revenue ($M) and Market Share (%) of Major Players, 2017, Table 7: Ophthalmic Devices, Saudi Arabia, Revenue ($M) and Market Share (%) of Major Companies, 2017, Table 8: Hospital Supplies Market, Saudi Arabia, Revenue ($M) and Market Share (%) of Major Companies, 2017, Table 9: Market Shares of Health Insurance Companies, Saudi Arabia, 2017, Table 10: Total Performance Target, Saudi Arabia, 2019, Table 11: MDMA Evaluation Fees, Saudi Arabia, 2016, Table 12: License Or Renewal Fee ($), 2019, Saudi Arabia, Table 13: Profit Margin (%), 2019, Saudi Arabia, Table 14: Customs Ports, 2015, Saudi Arabia, Table 15: Patent Fees ($), 2019, Saudi Arabia, Table 16: Trademark Fees ($), 2019, Saudi Arabia, Table 17: Label of a Pharmaceutical Product, Saudi Arabia, 2019, Table 18: Minimum Particulars to Appear on Blisters or Strips , Saudi Arabia, 2019, Table 19: Minimum Particulars to Appear on Small Immediate Packaging, Saudi Arabia, 2019, Table 20: Recommendations for Using Color, Saudi Arabia, Table 21: Recommendations for Primary Packaging, Saudi Arabia, Table 22: Recommendations for Secondary Packaging, Saudi Arabia, Figure 1: Pharmaceutical Market, Saudi Arabia, Revenue ($B), 2013–2018, Figure 2: Medical Device Market, Saudi Arabia, Revenue ($B), 2015–2020, Figure 4: 2018–19 Deal Overview By Region, Figure 5: Country Profile, Saudi Arabia, 2018, Figure 6: Pharmaceutical Market, Saudi Arabia, Revenue ($B), 2011–2018, Figure 7: Pharmaceutical Market, Saudi Arabia, Revenue Forecast ($B), 2019–2025, Figure 8: Pharmaceutical Market, Saudi Arabia, Pharmaceutical Exports, Figure 9: Pharmaceutical Market, Saudi Arabia, Top Export Partners, Figure 10: Pharmaceutical Market, Saudi Arabia, Pharmaceutical Imports, Figure 11: Pharmaceutical Market, Saudi Arabia, Top Import Partners, Figure 12: Innovation Centers, Saudi Arabia, 2019, Figure 13: Biosimilars, Saudi Arabia, 2019, Figure 14: Major OTC Drug Classes (Share %), Saudi Arabia, 2018, Figure 15: Pharmaceutical Market, Supply Chain, Saudi Arabia, Figure 16: Pharmaceutical Market, Saudi Arabia, Sales of Patented Drug Products by Major Therapeutic Class, 2010–2015, Figure 17: Pharmaceutical Market, Major Players, Saudi Arabia, Figure 18: Medical Device Market, Saudi Arabia, Revenue ($B), 2015–2020, Figure 19: Medical Device Market, Saudi Arabia, Revenue Forecast ($B), 2021–2025, Figure 20:Medical Device Market, Saudi Arabia, Revenue by Segment ($B), 2018, Figure 21: Nephrology and Urology Device Market, Saudi Arabia, Revenue ($B), 2015–2022, Figure 22: Nephrology and Urology Device Market, Saudi Arabia, Market Share of Major Players (%),2017, Figure 23: Drug Delivery Devices Market, Saudi Arabia, Revenue ($B), 2015–2022, Figure 24: Drug Delivery Devices Market, Saudi Arabia, Market Share of Major Players (%), 2017, Figure 25: Healthcare IT Market, Saudi Arabia, Revenue ($B), 2015–2022, Figure 26: Healthcare IT Market, Saudi Arabia, Market Share of Major Players (%), 2017, Figure 27: Ophthalmic Devices, Saudi Arabia, Revenue ($B), 2015–2022, Figure 28: Ophthalmic Devices, Saudi Arabia, Market Share of Major Players (%), 2017, Figure 29: Hospital Supplies Market, Saudi Arabia, Revenue ($B), 2015–2022, Figure 30: Hospital Supplies Market, Saudi Arabia, Market Share of Major Companies (%), 2017, Figure 31: Diagnostic Market, Saudi Arabia, Revenue ($B), 2015-2020, Figure 32: Diagnostic Market, Saudi Arabia, Revenue ($B), 2021–2025, Figure 33: Medical Device Market – Major Players, Figure 34: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Saudi Arabia, 2018–2019, Figure 35: Deal Value and Deal Count Sub-Types, Pharmaceutical Market, Saudi Arabia, 2018–2019, Figure 36: M&A Deals by Therapy Area, Pharmaceutical Market, Saudi Arabia, 2018–2019 (by value and by number), Figure 37: Structure of the Healthcare Sectors, Saudi Arabia, Figure 38: Organizational Chart of Ministry of Health, Saudi Arabia, Figure 39: NTP Strategy to Transform Healthcare, Saudi Arabia, 2018, Figure 40: Formulary Additions, Saudi Arabia, Figure 41: Insurance System of GOSI, Saudi Arabia, 2019, Figure 42: Health Insurance Market, Revenue ($B), Saudi Arabia, 2018, Figure 43: OOP Expenditure (% of total expenditure on health), Saudi Arabia, 2010–2016, Figure 44: Annual Rate of Change (%), Health Price Index, Saudi Arabia, 2010–2018, Figure 45: SFDA, Organizational Structure, Saudi Arabia, 2018, Figure 46: MAA Submission Process, Saudi Arabia, Figure 48: Drug Licensing Renewal, Saudi Arabia, Figure 49: Patent Application Process, Saudi Arabia, 2018, Figure 50: Number of Hospitals, Saudi Arabia, 2010–2018, Figure 51: Diagnostic Equipment, Saudi Arabia, 2015–2018, Figure 52: Hospital Beds (per 10,000 population), Saudi Arabia, Figure 53: OBS/Gyn and Pediatric Hospital Beds of MoH (per 10,000 population), Saudi Arabia, Figure 54: Psychiatric Hospital Beds of MoH (per 10,000 population), Saudi Arabia, Figure 55: Life Expectancy (Years), 2010–2018, Saudi Arabia, Figure 56: Immunization Rate (%), 2010–2018, Saudi Arabia, Figure 57: PM2.5 (µg/m3), Saudi Arabia, 2010–2017, Figure 58: CO2 Emissions (Million of Tons), Saudi Arabia, 2010–2018, Figure 59: Physicians (per 10,000 population), Saudi Arabia, 2010–2018, Figure 60: Dentists (per 10,000 population), Saudi Arabia, 2010–2018, Figure 61: Nurses (per 10,000 population), Saudi Arabia, 2010–2018, Figure 62: Pharmacists (per 10,000 population), Saudi Arabia, 2010–2018, Figure 63: Major Causes of Mortality (number of deaths), Saudi Arabia, Figure 64: Major Causes of Male Mortality (number of deaths), Saudi Arabia, Figure 65: Major Causes of Female Mortality (number of deaths), Saudi Arabia, Figure 66: DALYs by Major Disease (‘000), Saudi Arabia, Figure 67: Healthcare Expenditure as Percentage of GDP (%), Saudi Arabia, 2010–2016, Figure 68: Public-Private Share (%), Saudi Arabia, 2010–2016. As shown in Table 5, the price comparison was conducted for esomeprazole (40 mg) gastro-resistant coated tablets, available in a package size of 28 tablets. External price referencing refers to the practice of determining the price of a medicine in a given country by considering the prices of the medicine in other countries in which the product is marketed. In this study, there were significant differences in the prices of the generic medicines for the same molecule. Use of generics—a critical cost containment measure for all healthcare professionals in Europe? ex-factory price, a weighted, one-year average, disclosed price (WADP) is calculated. However, the private healthcare sector has grown in recent years and is now considered an essential component of the Saudi healthcare system [1–3]. 2009;9(1):150. Wanis H. Pharmaceutical pricing in Egypt. 2010;3(3):471-81. However, imported generic medicines with high technological features are priced 30%–35% lower than the innovator’s product [41]. 4. 10. Fitch Solutions Group. WHO guideline on country pharmaceutical pricing policies. Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025 - ResearchAndMarkets.com ... Saudi Arabia - Pharmaceutical Pricing & Reimbursement Policies . 4. Business Monitor International. The aim of this study was to provide an overview of the current pharmaceutical pricing policy for medicines in Saudi Arabia and to provide an evaluation of the impact of this policy on medicine prices. Meanwhile, companies licensed under the Saudi Food and Drug Authority (SFDA) are allowed to import the products in commercial quantities and customs have listed the following five reasons for exempting goods returned for export abroad from reimbursement of duties. However, the price of the first generic medicine is relatively close to the post-patent price of the original brand medicine. This article discusses the pharmaceutical pricing policies and the impact of health drug prices on the public in the Kingdom of Saudi Arabia. References The second registered generic medicine will be priced 10% lower than the set price of the first registered generic medicine. 37. HÃ¥konsen H, Sundell KA. Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. 3.2 Procurement & Reimbursement Policies. Saudi Pharm J. 2020;9(1):14-21.DOI: 10.5639/gabij.2020.0901.003. Appl Health Econ Health Policy. Saudi Pharm J. Over the past few years, Saudi Arabia has witnessed exponential economic growth and fortune, which is followed by the swift technological … Apparel, Accessories, Luggage and Leather Goods (259), Cash and Carries and Warehouse Clubs (174), Drug Stores and Health and Beauty Stores (296), Hypermarkets, Supermarkets and General Merchandise Retailers (374). Pharmaceutical pricing policy Ministry of Health of Saudi Arabia. Pharmaceutical expenditure and total health-care expenditure in OECD countries and China: bidirectional Granger causality on the basis of health level. Price comparison between innovator and generic medicines sold by community pharmacies in the State of Penang, Malaysia. Available from: http://www.who.int/medicines/areas/coordination/Saudi_ArabiaPSCP_Narrative2012-04-18_Final.pdf Dunlop WC, Staufer A, Levy P, Edwards GJ. Policies to enhance prescribing efficiency in Europe: findings and future implications. Generics and Biosimilars Initiative Journal. Medicine prices are determined according to pharmaceutical pricing rules and policies, which were approved by the Saudi FDA and have been implemented since November 2011 [36]. The overall generic medicine to original brand medicine price ratio was 0.87–0.30. The price ratio of generic medicine to the original brand medicine was 0.81. You may contact us at any time to opt-out. KD Market Insights provides a forecast for Saudi Arabia Pharmaceutical Market for a span of 6 years i.e. Medicine prices are strictly controlled through the pharmaceutical pricing policy in Saudi Arabia. Simoens S. A review of generic medicine pricing in Europe. Accounting for over 60% of the GCC, the pharmaceuticals industry in Saudi Arabia records over 4000 patented and generic drugs. However, the percentage of price reductions at which generic medicines must be priced lower than the original brand medicine, as well as the additional steps, vary widely between countries [32]. This is commonly evaluated through heath technology assessment (HTA) or pharmacoeconomic evaluations, such as cost-effectiveness analysis, cost minimization, and cost–benefit analysis [11, 32]. 40. However, the price difference between the other subsequent generic versions and the original brand medicine varies widely, but generally it is considered large. Consumers’ perceptions on generic medicines in Taif city, Saudi Arabia. By comparison, the study by Zeng (2013) reported that in China the difference was 0.34 and 0.98 [, In fact, in addition to the initial reductions in the prices of medicines, there are different subsequent methodological specifications, strategies, and interventions that lead to further reductions in medicine prices in many countries [, Disclosure of Conflict of Interest Statement is available upon, Alian A Alrasheedy, BPharm(Hons), MPharm(Clin), PhD, MACP, RPh. AlKhamees OA, AlNemer KA, Maneea MWB, AlSugair FA, AlEnizi BH, Alharf AA. East Mediterr Health J. In addition, a generic price link policy was adopted in Saudi Arabia. Alkhuzaee FS, Almalki HM, Attar AY, Althubiani SI, Almuallim WA, Cheema E, et al. 2. Arabic. Moreover, only 47.9% of physicians surveyed by Salhia et al. In this model, the price of the prescription medicine is reduced in a stepwise manner after patent expiration of the innovator product. For example, in South Korea, upon expiration of the patent, the price of the original brand medicine is reduced by 30%. Moreover, similar to many other countries, this has steadily increased in recent years. The price reductions depend on the annual sales of the original brand medicine before generic competition, as well the time of generic competition establishment. The Saudi Arabia Pharmaceuticals market estimated to be valued US$ 5,748 Mn in 2017 and poised to grow at CAGR 6.7%. The "Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025" report has been added to ResearchAndMarkets.com's offering. In addition, the prices of off-patent medicines are required to be reduced by 15%–19% upon registration of the 1st generic medicine [14, 42]. Yoo K-B, Lee SG, Park S, Kim TH, Ahn J, Cho M-H, et al. The New Pricing and Reimbursement Decree replaces the Resolution no. National trends in prescription drug expenditures and projections for 2018. Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. Generic medicines are priced by taking into consideration the criteria as stipulated in. Xiong Y, Cui Y, Zhang X. 2018;38(3):269-78. If the original brand is manufactured locally under license agreement with the license holding company, it will be given the same registered price as the imported original brand. Cost Eff Resour Alloc. Please let us know if you agree to our use. Pataky R, Tran DA, Coronado A, Alvi R, Boehm D, Regier DA, et al. As shown in Table 3, the price comparison was conducted for diclofenac sodium (50 mg tablets), available in a package size of 20 tablets. Accordingly, a price reduction is made if the current ex-factory price is higher than 10% of the WADP (i.e. 2011;1:141. Hence, the price comparison was conducted among its generic versions that are currently registered in Saudi Arabia. As a pricing strategy, special pricing agreements (also called innovative agreements or managed entry agreements) are adopted by some countries such as Australia, France, Germany, New Zealand, Spain, Taiwan, Thailand and the UK [11, 33]. 19. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. These agreements are used to facilitate the entry and funding of some new medicines, especially when it is challenging to determine the prices of newly launched medicines because of the uncertainty of their future effectiveness and the value that the medicine will offer in real life situations, beyond just clinical trials [33]. Saudi Arabia - Regulatory Aspects of Pharmaceutical Products 4.1 Gulf Central Committee for Drug Registrations (GCC-DR) 4.2 Regulatory Review Process 4.3 Centralized Registration 4.4 Decentralized Drug Registration Regulation 5. Our reimbursement experts can assist you in finding the answers to coding and reimbursement questions. Amoxicillin/clavulanic acid Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MIM, et al. Copyright © 2020 Pro Pharma Communications International. Saudi security forces have foiled three attempts to smuggle banned drugs into the Kingdom, the Ministry of Interior said on Thursday. 5. In this study, there were large differences in the prices of generic medicines for the same molecule. In tendering procedures, the pharmaceutical companies and manufacturers submit quotations for a particular contract in a competitive bidding process. Author: Alian A Alrasheedy, BPharm(Hons), MPharm(Clin), PhD, MACP, RPh, Dean, Unaizah College of Pharmacy, Qassim University, Saudi Arabia. However, the price of the first generic medicine is relatively close to the post-patent price of the original brand medicine. Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: a questionnaire based study. 2014;5:106. There was a large variation among the prices of the generic versions of atorvastatin, with the generic medicine to generic medicine price ratio was 0.87–0.18. The "Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025" report has been added to ResearchAndMarkets.com's offering. 43. The medicine prices were obtained from Saudi FDA’s official list of registered medicines and herbal products (available at https://www.sfda.gov.sa/en/drug/search/Pages/default.aspx) [39]. Vitry AI, Thai L, Roughead EE. Please contact client services for any further information: Apparel, Accessories, Luggage and Leather Goods, Hypermarkets, Supermarkets and General Merchandise Retailers. In this policy, which is based on the actual selling price, i.e. 24. These include pharmaceutical pricing policies and related strategies to control medicine prices and to ensure appropriate and stable prices. Available from: https://www.moh.gov.sa/Ministry/Rules/Documents/008.pdf Kwon H-Y, Yang B, Godman B. Approximately three quarters of the healthcare services are currently provided by the public sector. Experienced in pharmacoeconomics and evidence based medicine, drug reimbursement (value proposition and health economic model critique), global HTA agencies processes, Has more than 7 pharmacoeconomic studies published in peer-review journals. Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis. Similarly, among generic medicines, the absolute price difference between the highest price generic medicine and other generic medicines and the price ratio of the highest price generic medicine to other generic medicines of the same molecule were calculated [, The study compared the prices of the top selling medicines in Saudi Arabia, including six different medicines. Global Vernal Keratoconjunctivitis (VKC) Industry Insights 2017-2030: Epidemiology, Pipeline, Drugs, Reimbursement Scenario, Unmet Needs, Competitive Intelligence ... followed by Saudi Arabia. However, the price of the first generic medicine was close to the price of original brand medicine, with the first generic medicine-to-original brand medicine price ratio was 0.87–0.81. 3. Pharmaceutical pricing in Europe. The report provides information on the healthcare, regulatory, and reimbursement landscape in the Saudi Arabia, and includes: • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers, • Profiles and SWOT analyses of the major players in the pharmaceutical market (GlaxoSmithKline, Novartis, Pfizer, Tabuk Pharmaceuticals and Saudi Arabian Pharmaceutical Industries & Medical Appliances Corp) and profiles and SWOT analyses of the major players in the medical device market (Cardinal Health, Fujitsu, AstraZeneca, GE Healthcare, and Kimberly-Clark Corporation), • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Saudi Arabia, • Porter’s five forces analysis for pharmaceutical and medical devices market of Saudi Arabia, • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs, • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure, • An overview of the opportunities and challenges to growth in the Saudi Arabian healthcare market. GlobalData UK Ltd is a wholly owned subsidiary of GlobalData PLC, with company number 03925319. 2018;6(3):E292-E9. active ingredients, in which their products were listed in the top 10 products sold in Saudi Arabia during the period of 2010–2015 [37]. If the original brand is manufactured by a local manufacturer with license agreement with the license holding company as a second brand, it will be given the same price as the original brand during the patent protection period, and after patent expiration the second local brand will be treated as the first generic medicine in terms of pricing. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Saudi Arabia. A price comparison between the original brand medicines and their generic versions was conducted for the top six selling medicines in Saudi Arabia during the period of 2010–2015. In 2018, the nation executed at least 59 peoplefor drug crimes, according to Harm Reduction International. Therefore, the aim of this article was to provide an overview of the current pharmaceutical pricing policy of medicines in Saudi Arabia and to provide an evaluation of the impact of this policy on medicine prices, including both the original brand medicines and generic medicines. Permission granted to reproduce for personal and non-commercial use only. This policy has been implemented in many European countries, such as Austria, Belgium, Switzerland, Germany, Estonia, Finland, France and Ireland [32]. retail prices for consumers. The generic medicine to original brand medicine price ratio was 0.87–0.46. 2012;1(2):69-83. doi:10.5639/gabij.2012.0102.017 Submitted: 1 October 2020; Revised: 23 January 2020; Accepted: 6 February 2020; Published online first: 19 February 2020. Generics and Biosimilars Initiative Journal (GaBI Journal). the association between low price and low quality and effectiveness, as reported in the literature [49–52]. Saudi ArabiaSaudi Arabia Pricing Regulations •Article 12: Pricing Regulations - Calculation of drug price is based on Ex-factory or Cost, Insurance and Freight (CIF) price into Saudi Arabia in the currency of the country of origin, or, the currency specified by the Ministry of Health. 2013;2(1):18-22. There was only one generic version of esomeprazole during the study period. Saudi Arabia Bans Individuals from Importing E-Cigarettes ... Saudi Customs have stipulated five reasons for reimbursement of their duties. In Saudi Arabia, public drug prices are strictly regulated by the SFDA. Pharmaceutical Policy in Countries with Developing Healthcare Systems: Springer; 2017. p. 329-47. Then, the company or manufacturer that offers the best bid wins the tender based on the specified criteria [11, 22]. Knowledge attitude and perception of dispensing doctors regarding generic medicines in Karachi, Pakistan: a qualitative study. In addition, market completion can further decrease medicine prices. No medication, either brand or generic, can be registered without being priced first by the SFDA [42] . Saudi Arabia Pharmaceuticals & Healthcare Report Q3 2015. Arabic. Globally, in terms of the pricing of medicines, several strategies are used, including external price referencing (also called international price benchmark/referencing), internal price referencing, value-based pricing, tendering and negotiations, and special pricing agreements [11, 32]. Shafie AA, Hassali MA. In Saudi Arabia, public drug prices are strictly regulated by the SFDA. Arabic. 21. The generic medicine to original brand medicine price ratio was 0.81–0.58. 2015 [homepage on the Internet]. 2018;16(1):8. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. 5.1 Market Analysis. To ensure the accuracy of the comparisons, only medicines of the same properties were included [38]. 1. [cited 2020 Jan 23]. 2019;54(4):752-63. 45. Vogler S, Martikainen JE. CHAPTER 8 BIBLIOGRAPHY 110 - … Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. Pharmaceutical prices in the 21st century: Springer; 2015. p. 1-23. Two Egyptians and a Pakistani were executed on New Year’s Day. Pharmaceutical Expenditure. In Egypt, the original brand medicine price is fixed by selecting the lowest price in the region where the medicine is marketed. 33. Moreover, only products that were currently marketed in the country were considered, i.e. Saudi ArabiaSaudi Arabia Pricing Regulations •Article 12: Pricing Regulations - Calculation of drug price is based on Ex-factory or Cost, Insurance and Freight (CIF) price into Saudi Arabia in the currency of the country of origin, or, the currency specified by the Ministry of Health. The overall generic medicine to original brand medicine price ratio was 0.87–0.30. In Saudi Arabia, according to Pharmaceutical Institutions, and Product Law, retail pharmaceutical prices must be officially approved before marketing any pharmaceutical product [34, 35]. These factors include the increase in the prevalence of diseases, e.g. 44. The price comparisons for each medicine are presented in, The current approach adopted for medicine pricing is the ‘prescriptive pricing approach’ for both original brand medicines and generic medicines. Generics and Biosimilars Initiative Journal (GaBI Journal). An Overview About Rare Diseases in Saudi Arabia and Reimbursement of Orphan Drugs Mai F. Alsaqa’by1*, Nagwa Ibrahim2 1 Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Conclusion: Medicine prices are strictly controlled through the pharmaceutical pricing policy in Saudi Arabia. The public sector is funded mainly by the government budget while the private sector is financed by the cooperative health insurance schemes and out-of-pocket payments [1, 2]. However, more initiatives and investment have started in recent years to stimulate the pharmaceutical production as part of a strategic plan to produce at least 40% of all medicines locally on the long term [1, 5]. 2018;26(2):211-6. 41. Saudi Arabia is one of the rapidly growing economies in the world and its pharmaceuticals market is one of the most lucrative in the Middle East. Internal price referencing refers to the practice of determining the price of a medicine by considering the prices of its identical, similar, or therapeutically equivalent medicines within the same country.

saudi arabia drug reimbursement

Thirsty Camel Cask Wine, Klipsch Bar 48, Where To Buy Purple Sweet Potato In Perth, Oaties Biscuits Aldi Ingredients, Steps In Data Mining Process, West Bengal Is Famous For Which Food,